Eldridge, George A.
George Eldridge is the Chief Financial Officer at Abcuro. He brings over 30 years of experience in fundraising, taking companies public, facilitating mergers and acquisitions, and establishing critical financial operations. Most recently, George served as Chief Financial Officer at Aerovate Therapeutics guiding the company though its successful initial public offering (IPO) in 2021 and subsequent
George A. Eldridge, MBA
Chief Financial Officer
George A. Eldridge, MBA
Chief Financial Officer
George Eldridge is the Chief Financial Officer at Abcuro. He brings over 30 years of experience in fundraising, taking companies public, facilitating mergers and acquisitions, and establishing critical financial operations. Most recently, George served as Chief Financial Officer at Aerovate Therapeutics guiding the company though its successful initial public offering (IPO) in 2021 and subsequent reverse merger with Jade Biosciences in 2025. Before this, he served as Senior Vice President and Chief Financial Officer of Proteon Therapeutics. Earlier, George spent four years as a consultant to various companies in the biotechnology industry, acting as a Chief Financial Officer and providing advisory services. George has also held Chief Financial Officer roles at Targanta Therapeutics, until its acquisition in 2009 by The Medicines Company, Therion Biologics, Curis (previously Ontogeny, Inc.) and Boston Life Sciences. Earlier in his career, George was an investment banker at Kidder Peabody & Co, Inc. He holds a BA from Dartmouth College and an MBA from the University of Chicago, Booth School of Business.
Cupples, Courtney
Courtney Cupples is the Chief Commercial Officer at Abcuro and brings more than 25 years of global experience in commercializing orphan drug medicines for rare diseases. Prior to joining Abcuro, Courtney served as Chief Commercial Officer for Priovant Therapeutics, where she led commercial launch preparation for the company’s oral small molecule, brepocitinib, currently in development
Courtney Cupples
Chief Commercial Officer
Courtney Cupples
Chief Commercial Officer
Martin, Alex
Alex Martin brings over 30 years of experience building companies and closing transactions in the biopharmaceutical industry. He was most recently Chief Executive Officer of Palladio Biosciences, a clinical stage biopharmaceutical company which was acquired by Centessa Pharmaceuticals (CNTA), and previously served as Chief Executive Officer of Realm Therapeutics (RLM) which was acquired by ESSA
Alex Martin, MBA
Chief Executive Officer
Alex Martin, MBA
Chief Executive Officer
Tubridy, Karen
Karen Tubridy is the Chief Operating Officer of Abcuro. She brings more than 30 years of experience in drug development strategy and operations supporting novel and first-in-class therapeutics. Previously, Karen served as a Chief Development Officer at Verseau Therapeutics, Akebia Therapeutics, and Eleven Bio. She has had responsibility for driving global program strategies to IND,
Karen Tubridy, PharmD
Chief Operating Officer
Karen Tubridy, PharmD
Chief Operating Officer
Wilkins, Jeffrey
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among
H. Jeffrey Wilkins, MD
Chief Medical Officer
H. Jeffrey Wilkins, MD
Chief Medical Officer
Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory approval. Jeff has deep expertise in the areas of immunology, rare diseases, and immuno-oncology. He has served in senior clinical leadership positions, including as Chief Medical Officer for over 20 years. Among others, Jeff led clinical development programs at Avalo Therapeutics, Lycera, Ceptaris Therapeutics, Cephalon, and Ception Therapeutics. He entered the pharmaceutical industry with GlaxoSmithKline, where he rose to become Vice President of Discovery Medicine for GSK’s Center of Excellence in External Drug Discovery. Jeff received his MD from Temple University School of Medicine and his BS from Bucknell University.
